Thus, MSC-delivered sTRAIL in combination with AKTi (or other appropriate co-treatments) is a potential future therapeutic approach for advanced prostate cancer and other difficult to treat tumour types, as it enables TRAIL to induce apoptosis and prevents or reduces the production of harmful cytokines at the same time. Here, TNFSF10 is linked to prostate carcinoma.